TrialArthritis & rheumatology (Hoboken, N.J.)2020

Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.

Yusuf Yazici et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.